memo-inOncology – SPECIAL ISSUE
Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.
The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.
REGISTER
Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.
LATEST NEWS
memo – inOncology SPECIAL ISSUE
Congress Report virtual ESMO 2020 solid tumors
A GLOBAL CONGRESS DIGEST ON SOLID TUMORSReport from the ESMO Congress, 19th – 21st September 2020, virtual congress
memo – inOncology SPECIAL ISSUE
Congress Report virtual ESMO 2020 Lung Cancer
This report summarizes a selection of abstracts presented at ESMO 2020 Lung Cancer.
EXPERT VIDEOS
All videointerviews from virtual ESMO 2020 solid tumors
Andrés Cervantes talks about novel findings obtained in the field of gastric cancer, gastroesophageal junction adenocarcinoma and esophageal cancer as well as developments in hepatocellular carcinoma and investigational immunotherapies that might evolve into new treatment approaches.
All videointerviews from virtual ESMO 2020 lung cancer
Tony Mok summarizes insights into the immunotherapeutic management of patients with advanced lung cancer who receive PD-1 inhibitors and relates to aspects of biomarker-based treatment selection, patient prognosis, and new agents that might change the treatment landscape.
Byoung Chul Cho explains about the rationale and outcomes for combined targeted treatment of lung cancer patients with an emphasis on EGFR-mutant disease and describes findings obtained for a first-in-class agent targeting the KRASG212C mutation.
Maarten Lambrecht highlights aspects of radiobiology regarding interactions between radiotherapy and the immune system, non-invasive imaging biomarkers and trial results presented at ESMO 2020 that bear importance from a radiation oncologist’s point of view.
Paul Baas discusses the prognosis and treatment of patients with malignant mesothelioma, relating to combined modality treatment with immune checkpoint inhibitors plus chemotherapy and talks about other immunotherapeutic approaches beyond checkpoint inhibition.
